These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1683 related articles for article (PubMed ID: 8826613)

  • 1. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
    Bissery MC; Vrignaud P; Lavelle F; Chabot GG
    Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice.
    Bissery MC; Nguyen CH; Bisagni E; Vrignaud P; Lavelle F
    Invest New Drugs; 1993 Nov; 11(4):263-77. PubMed ID: 8157469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
    Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo.
    Tsuruo T; Matsuzaki T; Matsushita M; Saito H; Yokokura T
    Cancer Chemother Pharmacol; 1988; 21(1):71-4. PubMed ID: 3342468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
    Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
    Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
    Bissery MC; Guénard D; Guéritte-Voegelein F; Lavelle F
    Cancer Res; 1991 Sep; 51(18):4845-52. PubMed ID: 1680023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
    Kawato Y; Furuta T; Aonuma M; Yasuoka M; Yokokura T; Matsumoto K
    Cancer Chemother Pharmacol; 1991; 28(3):192-8. PubMed ID: 1855276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothec in, a novel water-soluble derivative of camptothecin, against murine tumors.
    Kunimoto T; Nitta K; Tanaka T; Uehara N; Baba H; Takeuchi M; Yokokura T; Sawada S; Miyasaka T; Mutai M
    Cancer Res; 1987 Nov; 47(22):5944-7. PubMed ID: 3664496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.
    Bissery MC; Vrignaud P; Lavelle F
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):3-16. PubMed ID: 8604451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antitumor activity of new derivatives of camptothecin].
    Nitta K; Yokokura T; Sawada S; Kunimoto T; Tanaka T; Uehara N; Baba H; Takeuchi M; Miyasaka T; Mutai M
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):850-7. PubMed ID: 3566296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
    Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
    Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral versus intraperitoneal administration of irinotecan in the treatment of human neuroblastoma in nude mice.
    Choi SH; Tsuchida Y; Yang HW
    Cancer Lett; 1998 Feb; 124(1):15-21. PubMed ID: 9500186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
    Zamboni WC; Houghton PJ; Thompson J; Cheshire PJ; Hanna SK; Richmond LB; Lou X; Stewart CF
    Clin Cancer Res; 1998 Feb; 4(2):455-62. PubMed ID: 9516936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
    J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human multidrug resistance associated protein 4 confers resistance to camptothecins.
    Tian Q; Zhang J; Tan TM; Chan E; Duan W; Chan SY; Boelsterli UA; Ho PC; Yang H; Bian JS; Huang M; Zhu YZ; Xiong W; Li X; Zhou S
    Pharm Res; 2005 Nov; 22(11):1837-53. PubMed ID: 16132345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
    Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
    Chabot GG
    Cancer Chemother Pharmacol; 1995; 36(6):463-72. PubMed ID: 7554037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models.
    Zamboni WC; Stewart CF; Cheshire PJ; Richmond LB; Hanna SK; Luo X; Poquette C; McGovren JP; Houghton JA; Houghton PJ
    Clin Cancer Res; 1998 Mar; 4(3):743-53. PubMed ID: 9533544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 85.